Biomarin Pharmaceutical (BMRN) Accumulated Expenses (2010 - 2019)

Biomarin Pharmaceutical has disclosed Accumulated Expenses across 10 years of filings, most recently posting $87.3 million for Q1 2019.

• Quarterly Accumulated Expenses rose 428.98% year-over-year to $87.3 million in Q1 2019, while the trailing twelve-month figure through Mar 2019 was $87.3 million (up 428.98% YoY) and the FY2018 annual result came in at $20.0 million, down 85.81% from the prior year.
• Accumulated Expenses rose to $87.3 million in Q1 2019, from $20.0 million in the prior quarter.
• Over five years, Accumulated Expenses peaked at $140.8 million in Q4 2017 and troughed at $9.5 million in Q2 2015.
• A 5-year average of $43.9 million and a median of $20.0 million in 2018 frame the typical range for Accumulated Expenses.
• Annual changes were most pronounced in 2015 — Accumulated Expenses tumbled 88.0% — and 2017, when it soared 829.19%.
• Tracing BMRN's Accumulated Expenses over 5 years: stood at $32.6 million in 2015, then tumbled by 53.46% to $15.2 million in 2016, then surged by 829.19% to $140.8 million in 2017, then slumped by 85.81% to $20.0 million in 2018, then surged by 336.8% to $87.3 million in 2019.
• Business Quant data shows BMRN's Accumulated Expenses at $87.3 million in Q1 2019, $20.0 million in Q4 2018, and $114.5 million in Q3 2018.